End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
781,000 KRW | +0.77% | -2.62% | +2.76% |
Apr. 25 | Samsung Bioepis Granted Approval to Market Autoimmune Treatment in Europe | MT |
Apr. 25 | Samsung Biologics Posts Higher Q1 Profit, Sales | MT |
ETFs positioned on Samsung Biologics Co.,Ltd.
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.63% | 2 M€ | -14.14% | ||
0.92% | 11 M€ | -.--% | - | |
0.43% | 15 M€ | +12.19% | ||
0.15% | 441 M€ | +4.34% | - | |
0.15% | 2,808 M€ | +7.07% | - | |
0.15% | 149 M€ | +2.23% | - | |
0.13% | 4 M€ | -4.41% | - | |
0.07% | 11 M€ | +1.81% | ||
0.05% | 117 M€ | -0.14% | - | |
0.04% | 7 M€ | +2.58% | - | |
0.02% | 34 M€ | +6.29% | - | |
0.01% | 302 M€ | +3.73% | - | |
0.01% | 39 M€ | +4.22% | - | |
0.01% | 389 M€ | +6.21% | - | |
0.01% | 108 M€ | +1.87% | - | |
0.01% | 17 M€ | +1.40% | - | |
0.01% | 147 M€ | +4.63% | - | |
0.01% | 52 M€ | -0.52% | - | |
0.01% | 8 M€ | -0.30% | - | |
0.00% | 7 M€ | +0.11% | - | |
0.00% | 34 M€ | +1.32% | - |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.76% | 40.17B | |
-3.93% | 86.16B | |
-16.48% | 31.47B | |
+55.89% | 25.24B | |
-13.58% | 15.82B | |
-9.12% | 11.96B | |
-42.56% | 11.61B | |
+5.99% | 8.84B | |
-2.11% | 7.93B | |
+1.55% | 7.68B |
- Stock Market
- Equities
- A207940 Stock
- Funds and ETFs Samsung Biologics Co.,Ltd.